Aurobindo Pharma shares shed ₹18.00 to close at ₹1,825.00 on the BSE on Wednesday, marking a 0.98% dip after American drug regulators escalated compliance scrutiny on its United States manufacturing footprint.
The selling followed an exchange disclosure confirming that the US Food and Drug Administration issued an Official Action Indicated (OAI) classification for the Seymour, Indiana facility operated by Lannett Company LLC. Lannett operates as a wholly owned step-down subsidiary of Aurobindo Pharma USA Inc., which sits under the parent pharmaceutical group.
Regulators inspected the Seymour site between August 17 and August 21, 2026, delivering four formal observations upon wrapping up the audit. Aurobindo Pharma submitted its remediation dossier within the stipulated deadline. Yet, the US drug authority maintained a hard line, delivering formal correspondence on November 11, 2026, that confirmed the OAI status.
An OAI classification signals that the US FDA uncovered regulatory deviations severe enough to warrant administrative sanctions and mandatory corrective actions before granting new product approvals from the site.
Market Context: The OAI notice lands as Indian generic drug manufacturers—including Sun Pharma, Aurobindo Pharma, and Dr. Reddy's—face steady pricing deflation across traditional generic oral solids in the US market, heightening the margin cost of regulatory remediation.
Aurobindo pushed back against operational panic in its regulatory disclosure, stating the regulatory classification will trigger zero disruption to its day-to-day manufacturing runs or top-line financial performance.
| Parameter | Detail |
|---|---|
| Operating Entity | Lannett Company LLC (Step-down subsidiary) |
| Facility Location | Seymour, Indiana, United States |
| Inspection Window | August 17–21, 2026 |
| Regulatory Action | Official Action Indicated (OAI) |
| Inspection Observations | 4 citations issued |
| Formal Notification Date | November 11, 2026 |
| BSE Closing Price | ₹1,825.00 (-0.98% / -₹18.00) |
| Operational & Financial Impact | Nil (per regulatory filing) |
The regulatory pushback strikes an otherwise profitable earnings stretch. Aurobindo Pharma recently posted a 33% surge in second-quarter net profit, beating street projections and approving an interim dividend of ₹7 per equity share.
And while Seymour faces heightened regulatory friction, other nodes across Aurobindo's manufacturing pipeline have cleared scrutiny. The company recently secured Voluntary Action Indicated (VAI) status for its Telangana unit, while its Unit II subsidiary received an Establishment Inspection Report (EIR) bearing a VAI classification from the US regulator.
The pharmaceutical company confirmed it will apprise stock exchanges of subsequent regulatory correspondence as mandatory corrective discussions proceed with the US FDA.